| Literature DB >> 36233362 |
Abstract
AIMS: Heart valve surgery is associated with a risk of serious postoperative complications including postoperative cardiogenic shock (described as postcardiotomy shock (PCS)). The indication for extracorporeal membrane oxygenation (ECMO) is cardiogenic shock, which is resistant to optimal causal and pharmacological treatment, including the supply of catecholamines and/or an intra-aortic balloon pump (IABP). The aim of this study was to assess the usefulness of the selected preoperative biomarkers in the prediction of postoperative cardiogenic shock requiring ECMO in patients undergoing heart valve surgery.Entities:
Keywords: NT-proBNP; cardiogenic shock; extracorporeal membrane oxygenation (ECMO); valve surgery
Year: 2022 PMID: 36233362 PMCID: PMC9570867 DOI: 10.3390/jcm11195493
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Baseline characteristics of the study population.
| Preoperative Characteristics of Patients ( | Values | Values | Values | |
|---|---|---|---|---|
| Age, years * | 63 ± 12 | 63 ± 11 | 65 ± 12 | Ns |
| Male: men, | 351 (57%) | 8 (53%) | 343 (57%) | Ns |
| Body mass index, kg/m2 * | 28 ± 8 | 26 ± 6 | 27 ± 8 | Ns |
| EuroSCORE II, % * | 3.5 ± 3.1 | 3.9 ± 3.5 | 3.5 ± 3.0 | 0.04 |
| NYHA, (classes) * | 2.5 ± 0.5 | 3 ± 0.5 | 2.5 ± 0.6 | 0.03 |
| LV ejection fraction, % * | 57 ± 12 | 55 ± 12 | 60 ± 12 | 0.04 |
| TAPSE, mm * | 22 ± 8 | 21 ± 7 | 22 ± 7 | Ns |
| RVSP, mmHg * | 44 ± 17 | 48 ± 17 | 40 ± 16 | 0.04 |
| Atrial fibrillation, | 266 (43%) | 6 (40%) | 260 (43%) | Ns |
| Diabetes mellitus, | 113 (18%) | 3 (20%) | 110 (18%) | Ns |
| NT-proBNP, pg/mL * | 2003 ± 1532 | 7053 ± 3532 | 1875 ± 1430 | 0.002 |
| Hs-TnT, ng/L * | 34 ± 28 | 91 ± 58 | 28 ± 15 | 0.009 |
| Creatinine, mg/dL * | 0.9 ± 0.5 | 1.4 ± 0.7 | 0.8 ± 5 | 0.02 |
| Hemoglobin, g/dL * | 13.6 ± 1.5 | 13.3 ± 1.3 | 13.8 ± 1.4 | 0.04 |
| Red cell distribution width, % * | 14.2 ± 1.7 | 15.1 ± 1.7 | 13.8 ± 1.6 | 0.009 |
| Intraoperavite and postoperative characteristics of patients: | ||||
| AVR, | 313 (51%) | 7 (46%) | 306 (51%) | Ns |
| AVP, | 17 (3%) | Ns | 17 (3%) | Ns |
| MVR, | 112 (18%) | 3 (20%) | 109 (18%) | Ns |
| MVR + AVR, | 53 (9%) | 2 (13%) | 51 (8%) | 0.04 |
| MVP, | 115 (19%) | 3 (20%) | 112 (18%) | Ns |
| Additional procedureCABG, | 90 (14%) | 2 (13%) | 88 (15%) | Ns |
| Aortic cross-clamp time, min * | 101 ± 32 | 122 ± 39 | 98 ± 30 | 0.01 |
| Cardiopulmonary bypass time, min * | 125 ± 55 | 143 ± 61 | 118 ± 43 | 0.03 |
| Postoperative major blending, | 47 (8%) | 4 (26%) | 43 (7%) | 0.009 |
Values are represented by the mean * and a measure of the variation of the internal standard deviation. Abbreviations: AVP: aortic valve plasty, AVR: aortic valve replacement, CABG: coronary artery bypass graft, MVP: mitral valve plasty, MVR: mitral valve replacement, Hs-TnT: high-sensitivity Troponin T, NT-proBNP: n-terminal of the prohormone brain natriuretic peptide, LV: left ventricle, NYHA: New York Heart Association, RVSP: right ventricular systolic pressure, TAPSE: tricuspid annular plane systolic excursion.
Univariate analysis of the predictive factors for the primary endpoint.
| Variable | Odds Ratio | 95% CI | |
|---|---|---|---|
| Hemoglobin, g/dL | 0.763 | 0.625–0.967 | 0.02 |
| NT-proBNP, pg/mL | 1.020 | 1.009–1.036 | 0.001 |
| RDW, % | 1.327 | 1.083–1.626 | 0.006 |
| Cardiopulmonary bypass time, min * | 1.048 | 0.986–1.114 | 0.07 |
Abbreviations: NT-proBNP: n-terminal of the prohormone brain natriuretic peptide, RDW: red cell distribution width, * denotes the variable that obtained the value closest to achieving statistical significance (p < 0.05).
Figure 1Area under the receiver operating characteristic (AUC) ROC curve of NT-proBNP for cardiogenic shock requiring extracorporeal membrane oxygenation following valve surgery.